Investors are eyeing AI stocks in the tech sector, but other industries are also utilizing AI for growth. Eli Lilly partners with Nvidia to develop an AI-driven innovation lab for drug discovery, investing up to $1 billion. This venture aims to improve success rates in pharmaceuticals. Eli Lilly stock shows potential alongside its strong market presence and dividend growth.

While Eli Lilly’s AI ventures may take time to pay off, the company’s dominance in weight management drugs and pipeline diversification make it an attractive investment option. The company’s revenue growth and promising pipeline candidates, including for diabetes and oncology, add to its appeal. Additionally, Eli Lilly’s consistent dividend increases make it a strong buy for investors.

Read more at Nasdaq: This Company Is Doubling Down on AI. Is the Stock a Buy?